Literature DB >> 19763204

The use of duloxetine in chronic bulimia nervosa: a case report.

Richard C Christensen1, Robert N Averbuch.   

Abstract

Selective serotonin reuptake inhibitors are routinely prescribed as off-label treatments for bulimia nervosa. There is, however, a paucity of literature addressing the efficacy of the serotonin norepinephrine reuptake inhibitors in the pharmacologic management of this disorder. This article describes a clinical situation in which duloxetine, a serotonin norepinephrine reuptake inhibitor, effectively treated a patient with long-standing bulimia nervosa, purging type, and comorbid generalized anxiety disorder.

Entities:  

Keywords:  Bulimia nervosa; duloxetine; pharmacological management; serotonin norepinephrine reuptake inhibitors; serotonin reuptake inhibitors

Year:  2009        PMID: 19763204      PMCID: PMC2743210     

Source DB:  PubMed          Journal:  Psychiatry (Edgmont)        ISSN: 1550-5952


  5 in total

1.  Successful treatment with duloxetine in a case of treatment refractory bulimia nervosa: a case report.

Authors:  Eric Hazen; Maurizio Fava
Journal:  J Psychopharmacol       Date:  2006-01-09       Impact factor: 4.153

2.  Treatment of bulimia nervosa with sertraline: a randomized controlled trial.

Authors:  W Milano; C Petrella; C Sabatino; A Capasso
Journal:  Adv Ther       Date:  2004 Jul-Aug       Impact factor: 3.845

3.  Treatment of bulimia nervosa with fluvoxamine: a randomized controlled trial.

Authors:  W Milano; C Siano; C Putrella; A Capasso
Journal:  Adv Ther       Date:  2005 May-Jun       Impact factor: 3.845

4.  Use of reboxetine in bulimia nervosa: a pilot study.

Authors:  Secondo Fassino; Giovanni Abbate Daga; Sonia Boggio; Lorenzo Garzaro; Andrea Pierò
Journal:  J Psychopharmacol       Date:  2004-09       Impact factor: 4.153

5.  Duloxetine in obese binge eater outpatients: preliminary results from a 12-week open trial.

Authors:  Paolo Leombruni; Luca Lavagnino; Filippo Gastaldi; Alessia Vasile; Secondo Fassino
Journal:  Hum Psychopharmacol       Date:  2009-08       Impact factor: 1.672

  5 in total
  1 in total

1.  Suprathreshold duloxetine for treatment-resistant depression, anorexia nervosa binge-purging type, and obsessive-compulsive disorder: a case report.

Authors:  Debra L Safer; Katherine D Arnow
Journal:  Innov Clin Neurosci       Date:  2012-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.